Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 30;9(11):1978-1988.
doi: 10.7150/jca.23716. eCollection 2018.

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer

Andrés Muñoz Martín  1 , Manuel Hidalgo  2 , Rafael Alvarez  3 , Virginia Arrazubi  4 , Joaquina Martínez-Galán  5 , Mercedes Salgado  6 , Teresa Macarulla  7 , Alfredo Carrato  8
Affiliations
Review

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer

Andrés Muñoz Martín et al. J Cancer. .

Abstract

The current management of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) is based on systemic chemotherapy. The results of the MPACT and PRODIGE clinical trials have demonstrated that the combination of nab-paclitaxel and gemcitabine (GEM) as well as FOLFIRINOX regimen result in improvement in overall survival when compared to GEM alone. Treatment guidelines now recommend either one of these two regimens as first line treatment for fit patients with mPDAC. Because no head-to-head comparison between the two regimens exists, the selection of one versus the other is based on clinical criteria. The design and eligibility criteria of these two clinical trials are dissimilar, making the results of the MPACT trial more applicable to the general population of patients with mPDAC. In addition, the combination of nab-paclitaxel and GEM is better tolerated and easier to administer in clinical practice than FOLFIRINOX. Furthermore, when the regimens are studied in comparable patient populations the efficacy results are very similar. Nanoliposomal irinotecan plus 5FU has recently demonstrated a significant increase in efficacy rates after a GEM-based treatment. Importantly, treatment of mPDAC should now be considered as a continuum care for patients who are fit, with second and even third line treatments. Different sequential treatment algorithms are proposed based on available data. In retrospective studies, patients who were managed with GEM-based regimens followed by fluoropyrimidine-based regimens appear to have the most favorable outcome.

Keywords: FOLFIRINOX; chemotherapy; metastatic disease; nab-paclitaxel + gemcitabine; pancreatic cancer; sequential treatment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

    1. Skelton WP 4th, Parekh H, Starr JS, Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer; 2017. Nov 7. doi: 10.1007/s12029-017-0021-z. - PubMed
    1. Hidalgo M, Álvarez R, Gallego J. et al. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol. 2017;19:667–681. - PMC - PubMed
    1. Martín AJ, Adeva J, Martínez-Galán J. et al. Pancreatic ductal adenocarcinoma: metastatic disease. Clin Transl Oncol. 2017;19:1423–1429. - PubMed
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17. - PubMed
    1. NCCN. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. Available at: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed February 20; 2017.